Summary
Systemic lupus erythematosus (SLE) patients are characterized by a low lymphocyte count, which is considered a specific disease marker and is related to disease activity. The membrane bound molecules CD25 and CD27 are expressed and released in a soluble CD25 (sCD25) and soluble CD27 (sCD27) form by activation of predominantly T cells. In previous studies it was claimed that sCD25 as well sCD27 might be used as parameters for activation of the immune system; a correlation between the sCD25 profile with the disease course in SLE patients was also shown.
To assess the relationship between lymphocyte count and these T cell activation markers, we performed a cross-sectional and a longitudinal study. In the longitudinal study three SLE patients who were known for a long time at our outpatient clinic were studied. Both T cell markers strongly correlated with each other and formed a reflection of the disease course. In all 7 periods of exacerbation, which we observed in the 3 investigated patients, both levels increased preceding this period; however, no correlation was found with the lymphocyte count. In the cross sectional study of 69 patients with SLE, sCD25 and sCD27 levels were correlated with defined disease manifestations; sCD25 was elevated in all periods of increased disease activity. The same holds true for sCD27, with the exception of patients with nephritis in which the highest levels were observed. Both profiles of sCD25 and sCD27 were strongly correlated during the whole disease course. Our data prove that in the pathogenesis of SLE an active recruitement of unprimed and primed T cells takes place.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Smith, K.A. Interleukin-2: inception, impact and implications. Science 1988, 240, 1169–1176.
Smith, K.A., Interleukin-2. Sci Am 1990, 262, 50–57.
Nelson, D.L., Kurman, C.C., Fritz, M.E., Boutin, B., Rubin, L.A. Production of soluble and cellular Interleukin-2 receptors by cord blood mononuclear cells following in vitro activation. Pediatr Res 1986, 20, 136.
Rubin, L.A., Jay, G., Nelson, D.L. The released Interleukin-2 receptor binds Interleukin-2 efficiently. J Immunol 1986, 137, 3841.
Symons, J.A., Wood, N.C., Di Giovine, F.S., Dull, G.W. Soluble IL-2 receptor in rheumatoid arthritis. J Immunol 1988, 8, 2612–2618.
ter Borg, E.J., Horst, G., Limburg, P.C., Kallenberg, C.G.M. Changes in plasma levels of Interleukin-2 receptor in relation to disease exacerbation and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1991, 82, 21–26.
Swaak, A.J.G., Groenwold, J., Aarden, L.A. Statins van Eps, L.W., Feltkamp, T.E.W. Prognostic value of anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1982, 41, 388–395.
van Lier, R.A.W., Borst, J., Vroom, Th.M., Klein, H., van Mourik, P., Zeylemaker, W.P., Melief, C.J.M. Tissue distribution and functional properties of Tp 55 (CD27) A novel T cell differentiation antigen. J Immunol 1987, 139, 1589–1596.
de Jong, R., Loenen, W., Brouwer, M., van Emmerik, L., de Vries, E.F.R., Borst, J., van Lier, R.A.W. Regulation of expression of CD27, a T cell specific member of a novel family of membrane receptors. J Immunol 1991, 146, 2488–2494.
Hintzen, R.Q., de Jong, R., Hack, C.E., Chamuleau, M., de Vries, E.F.R., van Berge I.J.M., Borst, J., van Lier, R.A.W. A soluble form of the human T cell differentiation antigen. CD27 is released after triggering of the T cell receptor/CD3 complex. J Immunol 1991, 147, 29–35.
De Jong, R. Activation and function of human T lymphocyte subsets. Thesis University Amsterdam 1992.
Hol, B.E.A., Hintzen, R.Q., van Lier, R.A.W, Alberts P.C., Out, T.A., Jansen, H.M. Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis. Am Rev Resp Dis, in press.
Hintzen, R.Q., de Jong, R., Hack C.E., Chamuleau, M., de Vries, E.F.R., den Berge, J.J.M., Borst, J., van Lier, R.A.W. A soluble form of the human T-cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol 1991, 147, 29.
Hintzen, R.Q., van Lier, R.A.W. Kuijpers, K.C., Baars, P.A., Schaasberg, W., Lucas, C.J., Polman, C.H. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1991, 35, 211.
Chamuleau, M.E.D., ten Berge, J.J.M., Schellekens, P.T.A., Wilmink, J.M., Hintzen, R.Q., van Lier, R.A.W. Serum levels of soluble CD27 in renal transplant recipient. Transplantation 1992, 54, 932.
Hintzen, R.Q., de Jong, R., Lens, S.M.A., Brouwer, M., Baars, P., van Lier, R.A.W., Regulation of CD27 expression in subsets T lymphocytes. J Immunol 1993, 151, 2426.
Rivero, S.J., Diaz-Jouanen, E., Alarcon-Segovia, D. Lymphopenia in systemic lupus erythematosus: clinical diagnostic and prognostic significance. Arthritis Rheum 1978, 21, 295–305.
Winfield, J.B., Winchester, R.J., Kunkel, H.G. Association of cold reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1975, 18, 587–594.
Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., Mc Shane, D.J., Rothfield, N.F., Schaller, J.G., Talal, N., Winchester, R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25, 1271–1277.
Swaak, A.J.G., Groenwold, J., Aarden, L.A., Feltkamp, T.E.W. Detection of anti-dsDNA as a diagnostic tool. Ann Rheum Dis 1981, 40, 45–49.
Swaak, A.J.G., Groenwold, J., Bronsveld, W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986, 45, 359–366. 22 Kassan, S.S., Lockskin, M.D. Central nervous system lupus erythematosus: the need for classification. Arthritis Rheum 1979, 22, 1382–1385.
Bonfa, E., Golombek, S.J., Lee, D.K., Skelly, S., Weissback, H., Brot, N., Elkon, K.B. Association between lupus psychosis and anti-ribosomal protein antibodies. New Engl J Med 1987, 317, 265–271.
Campen, D.H., Horwitz, D.A., Quismario, F.D., Ehresmann, G.R., Martin, W. Serum levels of Interleukin-2 receptor and activity of rheumatic diseases characterised by immune system activation. Arthritis Rheum 1988, 31, 1358–1364.
Wolf, R.E., Brelsford, W.G., Hall, V.C., Adams, S.B. Cytokines and soluble Interleukin-2 receptors in rheumatoid arthritis. J Rheumatol 1992, 19, 524–528.
Ward, M.M., Dooley, M.A., Christenson, V.D., Pisetsky, D.S. The relationship between soluble Interleukin-2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J Rheumatol 1991, 18, 235–240.
Airo, P., Bettenzioli, M., Gorla, R., Cattaneo, R. Increased concentration of soluble Interleukin-2 receptor in serum of patients with systemic sclerosis. Ann Rheum Dis 1991, 50, 270–271.
Raziuddin, S., Al-Janadi, W.A., Al-Wabel, A.A. Soluble Interleukin-2 receptor levels in serum and its relationship to T-cell abnormality and clinical manifestations of the disease in patients with Systemic Lupus Erythematosus. J Rheumatol 1991, 18, 831–836.
Seth, K.K., Nahei. Elevated titers of cell-free Interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome Immunol Lett 1986, 13, 179–184.
Turg, K.S.K., Kriland, E., Matznei, P. Soluble serum Interleukin-2 receptor levels in leprosy patients. Clin Exp Immunol 1987, 69, 10–15.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Swaak, A.J.G., Hintzen, R.Q., Huysen, V. et al. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheumatol 14, 293–300 (1995). https://doi.org/10.1007/BF02208342
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02208342